ORYX to Present Clinical Data for Therapeutic Vaccine MicOryx in Microsatellite Instable (MSI-H-) Colorectal Cancers at ASCO 2015

ORYX to Present Clinical Data for MicOryx in Microsatellite Instable (MSI-H-) Colorectal Cancers at ASCO 2015

Munich (Germany): ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today announced that clinical data of its MicOryx Phase I/IIa trial in colorectal cancer will be presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, on May 29 - June 02, 2015.

The poster “Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial” will be presented by Dr. Miriam Reuschenbach, research fellow at the German Cancer Research Center in Heidelberg, on Saturday, May 30, from 08:00 AM to 11:30 AM (CDT) in S Hall A and discussed from 03:00 PM to 04:15 PM (CDT) in Room S406 as part of the Developmental Therapeutics—Immunotherapy track.

“ASCO is an exciting opportunity for us to present first clinical data from our Phase I/IIa trial of the therapeutic vaccine MicOryx”, Dr. Bernard Huber, CEO and Founder of ORYX, commented. “To date, all the encouraging data strengthens our assumption that this therapeutic vaccine, directed against FSP antigens, is a promising approach for the treatment and cure of MSI-H colorectal cancers. We are proud that the investigators at the German Cancer Research Center, the Heidelberg University Hospital and the Nordwest Hospital, Frankfurt were recently honored with the prestigious Felix Burda Award for their work on the MicOryx project.”

The therapeutic vaccine MicOryx was evaluated in the open label, single center trial that included 22 advanced MSI-H colorectal cancer patients (UICC stage III or IV), who had received standard chemotherapy. The primary Phase I clinical trial endpoint was safety and toxicity (6 patients). The Phase IIa clinical trial evaluated the induction of cellular and humoral immune responses against MicOryx (16 patients) assessed by CT or MRI scans according to RECIST. The vaccine was safe and induced humoral and cellular immune responses.

The abstract is currently available on the ASCO website at: http://abstracts.asco.org/156/AbstView_156_149443.html

About ORYX:

ORYX is a privately held Munich based biotech company. ORYX develops three highly innovative drug candidates for the treatment of cancer, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. ORYX holds exclusive, world-wide licenses for all its development projects. For more information please visit: www.oryx-medicine.com

For further information, please contact:

Dr. Bernard Huber
Chief Executive Officer
ORYX GmbH & Co. KG
Phone: +49-8106-21-311-0
Email: info@no-spam-pleaseoryx-medicine.com

PR/IR contact
Katja Arnold
Executive Director MC Services AG
Phone: +49-89-210-228-40
Email: katja.arnold@no-spam-pleasemc-services.eu

Business Development
Dr. Dr. Sven Rohmann
Phone: +49-8106-21-311-0
Mobile: +41-7957-78895
Email: info@no-spam-pleaseoryx-medicine.com